Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article, J Clin Exp Oncol Vol: 7 Issue: 4
Combination of Daily Low Dose Cisplatin with Thoracic Radiation in Locally Non-Small Cell Lung Cancer for Fragile Patients: An Experimental Monocentric Serie
Clément-Duchêne Christelle1,2*, Salleron Julia3, Baumann Anne-Sophie4, Royer Philippe4, Faivre Jean-Christophe4, Ménard Olivier5, Vignaud Jean-Michel6, Prévot Michel7, Peiffert Didier4 and Beckendorf Véronique4
1Department of Oncology, Institut de Cancérologie de Lorraine, Nancy, France
2Centre de Recherche en Automatique de Nancy (CRAN), Nancy, France
3Department of Biostatistics, Institut de Cancérologie de Lorraine, Nancy, France
4Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France
5Department of Chest, CHU Nancy, France
6Department of Pathology, CHU Nancy, France
7Department of Pharmacy, CHU Nancy, France
*Corresponding Author : Clément-Duchêne Christelle
Department of Oncology, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne 54519 Vandoeuvrelès- Nancy, France
Tel: +33383598331
Fax: +33383598414
E-mail: c.clementduchene@nancy.unicancer.fr
Received: June 06, 2018 Accepted: July 10, 2018 Published: July 17, 2018
Citation: Christelle CD, Julia S, Sophie BA, Philippe R, Christophe FJ, et al. (2018) Combination of Daily Low Dose Cisplatin with Thoracic Radiation in Locally Non-Small Cell Lung Cancer for Fragile Patients: An Experimental Monocentric Series. J Clin Exp Oncol 7:4. doi: 10.4172/2324-9110.1000224
Abstract
Lung cancer incidence in the elderly is rising over year. The standard treatment for locally non-small cell lung cancer (NSCLC) is based on a combination of chemotherapy and thoracic radiation. No standard is described or validated for patients older than 70 years.
The objective of this retrospective study was to evaluate the toxicities and the feasibility of daily cisplatin at a dose of 6 mg/m² during thoracic irradiation (66-70 Gray) in NSCLC with poor WHO performance status, and/or comorbidities. The second objective was to obtain a first estimation of survival for patients with stage III-IV.
Between 2011 and 2015, 13 patients were retrieved from the hospital database. The median age was 71.3 years, and the most frequent histologic type was squamous cell carcinoma (69%). The most frequent grade 2 adverse events were cardiac (n=3) or digestive (n=1). No pulmonary toxicity was observed. For the 10 patients with stage III-IV, the median progression free survival was 171 months. The 1-year overall survival (OS) was 90%, and the 2-years OS was 67%.
The combination of daily cisplatin with thoracic radiation is effective, and well tolerated in fragile NSCLC patients. This association should be evaluated in clinical trials.
